首页> 外文OA文献 >44 An alginate oligomer (OligoG) developed as a dry powder for inhalation in cystic fibrosis demonstrates an excellent safety profile, similar to a nebulised solution used in a phase 2a trial

【2h】

44 An alginate oligomer (OligoG) developed as a dry powder for inhalation in cystic fibrosis demonstrates an excellent safety profile, similar to a nebulised solution used in a phase 2a trial

机译：44一种藻酸盐低聚物（OligoG），它是一种干粉，用于吸入性囊性纤维化，显示出优异的安全性，类似于2a期试验中使用的雾化溶液

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Myrset A.H.; Phillips L.; Moore S.A.; Dessen A.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. INHALED DRY POWDER ALGINATE OLIGOSACCHARIDE (OLIGOG) IN CYSTIC FIBROSIS: SUB-GROUP ANALYSES OF A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, EFFICACY AND SAFETY TRIAL [J] . Rye P., Pressler T., Smerud K. Respirology : . 2019,第S1期

机译：吸入干粉藻酸盐寡糖（Oligog）在囊性纤维化中：分组分析双盲，随机，安慰剂控制，疗效和安全试验
2. AN OPEN LABEL, RANDOMISED, TWO-WAY CROSSOVER SCINTIGRAPHIC STUDY TO INVESTIGATE LUNG DEPOSITION OF RADIOLABELLED ALGINATE OLIGOSACCHARIDE DELIVERED AS A DRY POWDER AND AS A NEBULISED SOLUTION IN CYSTIC FIBROSIS PATIENTS [J] . Hodges L., MacGregor G., Stevens H., Pediatric Pulmonology . 2014,第Suppla38期

机译：开放标签，随机化，双向交叉法研究以干粉形式和消囊溶液形式治疗的放射性标记藻酸盐寡糖在肺纤维化患者中的肺沉积
3. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients [J] . J. Stuart Elborn, David E. Geller, Douglas Conrad, Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society . 2015,第4期

机译：在稳定的囊性纤维化患者中评估左氧氟沙星吸入溶液（APT-1026）与妥布霉素吸入溶液的安全性和有效性的3期开放标签随机试验
4. Dry powder inhalable bacteriophage-polymeric particles reduce lung cystic fibrosis bacterial infections [C] . Rachit Aaarwal, Christopher Johnson, Barry Imhoff, Society for Biomaterials annual meeting and exposition . 2017

机译：干粉吸入性噬菌体多聚颗粒减少肺囊性纤维化细菌感染
5. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised double-blind placebo-controlled crossover phase 2b study [O] . Silke van Koningsbruggen-Rietschel, Jane C. Davies, Tacjana Pressler, 2020

机译：吸入干粉藻酸盐寡糖在囊性纤维化中：随机双盲安慰剂控制交叉相2B研究
6. WS5.5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection [O] . Goldman M., Schuster A., Halliburn C., 2012

机译：WS5.5一项随机，开放标签的3期研究，评估吸入性大黄酮酸钠（Colobreathe®）与妥布霉素雾化器溶液（TNS）的干粉制剂在患有慢性铜绿假单胞菌肺部感染的囊性纤维化受试者中的疗效和安全性

44 An alginate oligomer (OligoG) developed as a dry powder for inhalation in cystic fibrosis demonstrates an excellent safety profile, similar to a nebulised solution used in a phase 2a trial

著录项

相似文献

相关主题

期刊订阅